Research graph
References from Implications of drugs with rebate in Europe. Local targets link to admitted publications; unresolved targets remain external evidence.
The cost of cancer care in Europe 2018
10.1016/j.ejca.2020.01.011 · 2020 · External reference
The high price of anticancer drugs: origins, implications, barriers, solutions
10.1038/nrclinonc.2017.31 · 2017 · External reference
Prices and clinical benefit of cancerdrugs in the USA and Europe: a cost-benefit analysis
10.1016/s1470-2045(20)30139-x · 2020 · External reference
Managed Entry Agreements for oncology drugs: lessons from the European Experience to inform the future
10.3389/fphar.2017.00171 · 2017 · External reference
Innovation and drugs price and reimbursement: a comparison between Italy and the other major EU countries
10.5301/grhta.5000206 · 2015 · External reference
The impact of managed entry agreement on pharmaceutical prices
10.1002/hec.4112 · 2020 · External reference
10.1016/j.lanepe.2021.100050 · Admitted local publication
Payers’ experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia
10.1016/j.healthpol.2017.02.002 · 2017 · External reference
10.12968/eqhe.2019.50.28
10.12968/eqhe.2019.50.28 · External reference
Research and development spending to bring a single cancer drug to market and revenues after approval
10.1001/jamainternmed.2017.3601 · 2017 · External reference
